Jackie07
03-08-2011, 09:22 PM
Just saw on the Clinical Trial page of the hospital website that EMILIA (Trastuzumab-MCC-DM1 vs Capecitabine + Lapatninb) is available in my hospital. Thought I'd put it here in case anyone is interested in participating.
Temple is on I-35, just two hours drive from Dallas-Fort Worth and one hour from Austin. Waco is 40 minutes to the North, and Killeen/Fort Hood is 30 minutes to the West. Scott & White is the teaching hospital of Texas A&M University College of Medicine and has 20+ sattellite clinics around CentralTexas. It is the leader of rural health care in the nation. One of the S&W doctors served as the AMA President two years ago.
1-254-724-5407
www.sw.org (http://www.sw.org/)
http://clinicaltrials.gov/ct2/show/N...asms%22&rank=1 (http://clinicaltrials.gov/ct2/show/NCT00829166?term=TDM4370&cond=%22Breast+Neoplasms%22&rank=1)
#90009NCT00829166 (http://clinicaltrials.gov/ct2/show/NCT00829166?term=TDM4370&cond=%22Breast+Neoplasms%22&rank=1)
Title: A Randomized, Multicenter, Phase III Open-Label Study Of The Efficacy and Safety Of Trastuzumab-MCC-DM1 vs Capecitabine + Lapatninb In Patients With HER2-Positive Locally Advanced Or Metastatic Breast Cancer who Have Received Prior Trastuzumab-Based Therapy (EMILIA)
Study Location: Temple Main Campus
Temple is on I-35, just two hours drive from Dallas-Fort Worth and one hour from Austin. Waco is 40 minutes to the North, and Killeen/Fort Hood is 30 minutes to the West. Scott & White is the teaching hospital of Texas A&M University College of Medicine and has 20+ sattellite clinics around CentralTexas. It is the leader of rural health care in the nation. One of the S&W doctors served as the AMA President two years ago.
1-254-724-5407
www.sw.org (http://www.sw.org/)
http://clinicaltrials.gov/ct2/show/N...asms%22&rank=1 (http://clinicaltrials.gov/ct2/show/NCT00829166?term=TDM4370&cond=%22Breast+Neoplasms%22&rank=1)
#90009NCT00829166 (http://clinicaltrials.gov/ct2/show/NCT00829166?term=TDM4370&cond=%22Breast+Neoplasms%22&rank=1)
Title: A Randomized, Multicenter, Phase III Open-Label Study Of The Efficacy and Safety Of Trastuzumab-MCC-DM1 vs Capecitabine + Lapatninb In Patients With HER2-Positive Locally Advanced Or Metastatic Breast Cancer who Have Received Prior Trastuzumab-Based Therapy (EMILIA)
Study Location: Temple Main Campus